Naslov
Significant improvement of cardiac performance using sacubitril/valsartan in heart failure patient after heart transplantation

Autori
Gulin, Dario ; Čerkez-Habek, Jasna ; Planinić, Zrinka ; Adrović, Leon ; Šikić, Jozica

Izvornik
Cardiologia Croatica (1848-543X) 13 (2018), 11-12; 356-356

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, ostalo

Ključne riječi
heart failure, heart transplantation, sacubitril/valsartan

Sažetak
Ntroduction: Angiotensin receptor-neprilysin inhibitors have been introduced in the last few years as a new class of drugs for the treatment of heart failure (HF) patients. Its benefits have been proven in randomized control tri-als in HF patients, mostly with reduced ejection fraction. Recent studies reveal new indications and information about benefit in patients after myocardial infarction by re- ducing myocardial fibrosis and remodeling. Treatment of HF in patients after heart transplantation is challenging with limitations in therapeutic possibilities.1, 2 We present a case report of a heart transplant patient with significant clinical and echocardiographic improvement after sacu-bitril/valsartan introduction. Case report: 56-year-old patient, with a history of heart transplantation in 2014 due to ischemic cardiomyopathy, was hospitalized for HF. Dyspnea and reduced exercise tolerance had been worsening 2 months prior to hospi-tal admission. Echocardiography showed moderately reduced left ventricular systolic function (EF 32%), dif-fuse hypocontractility (GLPSavg -4%) and pulmonary artery hypertension (RSVP 65 mmHg), which did not dif-fer much from earlier examinations. In order to improve cardiac function, sacubitril/valsartan was added into treatment. 3 months later the patient was feeling much better with significantly improved physical activity toler-ance. Echocardiography exam showed improvement of left ventricular systolic function (EF 41%) and longitudinal myocardial deformation (GLPSavg -7.5%) with reduction of pulmonary artery hypertension (RSVP 50 mmHg). Conclusion: To our knowledge and available literature, sa- cubitril/valsartan has not been used in treatment of HF patients after heart transplantation. Significant clinical and echocardiographic improvement in short period of time after introduction of sacubitril/valsartan presents curiosity. Undoubtedly, such information requires further investigation

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA